Other Information.
−Removed: Marketing Agreement, by and between the Company and Fresenius Medical Care Deutschland GmbH, dated as of August 1, 2022.*
+Added: Sixth Amendment to the Amended and Restated Loan and Security Agreement, dated as of March 8, 2023, by and among CytoSorbents Corporation, CytoSorbents Medical, Inc.
+Added: and Western Alliance Bank (incorporate by reference to Exhibit 10.30 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022).
+Added: Consulting Agreement, dated March 31, 2023, by and between the Company and Ms.
+Added: Bloch (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 6, 2023).**
Certification of Principal Executive Officer pursuant to 18 U.S.C.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*
−Removed: Certification of Principal Financial Officer pursuant to 18 U.S.C.
+Added: Certification of Principal Interim Financial Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*
−Removed: The following materials from CytoSorbents Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) Consolidated Balance Sheets at September 30, 2022 and December 31, 2021, (ii) Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the three and nine months ended September 30, 2022 and 2021, (iv) Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 and (v) Notes to Consolidated Financial Statements.
+Added: The following materials from CytoSorbents Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, formatted in Extensible Business Reporting Language (XBRL):
+Added: (i) Consolidated Balance Sheets at March 31, 2023 and December 31, 2022, (ii) Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the three months ended March 31, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2023 and 2022 and (v) Notes to Consolidated Financial Statements.
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
−Removed: Portions of this exhibit are redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K and the schedules to this exhibit are omitted pursuant to Item 601(a)(5) of Regulation S-K.
* In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.
+Added: ** Portions of this exhibit identified by [***] have been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both not material and is private or confidential.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
CYTOSORBENTS CORPORATION
−Removed: November 3, 2022
/s/ Phillip P.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 3, 2022
/s/ Kathleen P.
−Removed: Chief Financial Officer
+Added: Interim Chief Financial Officer
(Principal Financial and Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.